Bausch + Lomb Corporation (NYSE:BLCO) Receives $17.25 Consensus Target Price from Analysts

Bausch + Lomb Corporation (NYSE:BLCO) has been given a consensus rating of “Hold” by the fifteen analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $17.25.

BLCO has been the subject of a number of research analyst reports. Evercore ISI set a $18.00 target price on Bausch + Lomb and gave the company an “in-line” rating in a report on Monday, January 5th. Royal Bank Of Canada raised their price objective on shares of Bausch + Lomb from $17.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, October 8th. Citigroup upgraded shares of Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th.

Institutional Investors Weigh In On Bausch + Lomb

Large investors have recently bought and sold shares of the stock. Woodline Partners LP raised its position in Bausch + Lomb by 0.5% in the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after purchasing an additional 1,436 shares in the last quarter. Blue Trust Inc. grew its position in shares of Bausch + Lomb by 58.5% during the second quarter. Blue Trust Inc. now owns 4,502 shares of the company’s stock worth $59,000 after buying an additional 1,662 shares in the last quarter. Gabelli Funds LLC increased its stake in shares of Bausch + Lomb by 0.5% during the second quarter. Gabelli Funds LLC now owns 444,000 shares of the company’s stock worth $5,776,000 after buying an additional 2,000 shares during the period. Ridgewood Investments LLC acquired a new stake in Bausch + Lomb in the second quarter valued at approximately $26,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after acquiring an additional 2,042 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Stock Down 1.5%

Shares of NYSE BLCO opened at $17.18 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.51 and a debt-to-equity ratio of 0.76. The business’s 50 day moving average is $16.63 and its two-hundred day moving average is $15.37. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $18.14. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of -19.75, a PEG ratio of 1.00 and a beta of 0.61.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.16 by $0.02. Bausch + Lomb had a positive return on equity of 2.42% and a negative net margin of 6.13%.The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the business posted $0.13 earnings per share. The company’s quarterly revenue was up 7.1% on a year-over-year basis. Research analysts predict that Bausch + Lomb will post 0.74 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.